Studies have shown that MASLD-HCC patients respond less favorably to immune checkpoint inhibitors compared to those with viral hepatitis-related HCC, possibly due to reduced tumor immunogenicity and the higher prevalence of exhausted CD8+ T cells [79]. This evidence concerns the gene CD8A and hepatocellular carcinoma.